Stock SALV SALVARX GROUP PLC
Add to a list
To use this feature you must be a member
Log inSign up

All News SalvaRx Group plc

Equities

SALV

IM00BZ4SS228

Delayed London S.E.
Other stock markets
 		5-day change 1st Jan Change
- GBX -.--% Intraday chart for SalvaRx Group plc -47.06% -.--%
2019 SalvaRx Evaluates Takeover Opportunities CI
2019 Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019 CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
SalvaRx : Portage Issues Common Shares and Warrants in Settlement of SalvaRx Loan Note Obligations
AQ
SalvaRx : Half Yearly Report 30 June 2019 RNS
PU
SalvaRx : RNS SalvaRx Group PLC interim report 30 June 2019
PU
SalvaRx Evaluates Takeover Opportunities
CI
Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019
CI
Salvarx Group plc Reports Earnings Results for the Full Year Ended December 31, 2018
CI
Portage Biotech Inc. (OTCPK:PTGE.F) completed the acquisition of SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile.
CI
SalvaRx Group plc Announces Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2018
CI
Portage Biotech Inc. (OTCPK:PTGE.F) (‘Portage’) entered into a conditional sale agreement to acquire SalvaRx Limited from SalvaRx Group plc, James Mellon and Greg Baile for $80.5 million.
CI
SalvaRx Group plc Announces Consolidated Earnings Results for the Year Ended December 31, 2017
CI
SalvaRx Seeks Acquisitions
CI
SalvaRx Announces an Unsecured $1 Million Loan
CI
SalvaRx Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2017
CI
SalvaRx Group plc Announces Final Audited Consolidated Earnings Results for the Year Ended December 31, 2016
CI
SalvaRx Seeks Investments
CI
SalvaRx Group plc Treats First Patient INT230-6 as Part of A Phase 1/2 International Clinical Study
CI
SalvaRx Group plc Reports Unaudited Consolidated Earnings Results for the Six Months Ended June 30, 2016
CI
Salvarx Group plc Announces Audited Consolidated Earnings Results for the Year Ended 31 December 2015
CI
SalvaRx Seeks Acquisitions
CI
Intensity Therapeutics, Inc. announced that it has received $10 million in funding from Batterson Venture Capital, LLC, Vcapital, Inc., Seed Innovations Limited, SalvaRx Group plc
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. SALV Stock
  4. News SalvaRx Group plc